top of page

Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline

Writer: nuaxia
nuaxia
1 hour ago
2 min read

Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.


Eli Lilly and Calytrix Bio announced on 16 November 2026 that they had signed a definitive acquisition agreement under which Calytrix shareholders may receive up to $1.5 billion in cash, consisting of an undisclosed upfront payment and additional consideration linked to future clinical and regulatory milestones.


The acquisition would add Calytrix's lead preclinical biparatopic antibody targeting mutant calreticulin to Lilly's precision haematology pipeline, with development focused on essential thrombocythaemia and myelofibrosis; the maximum headline value is contingent rather than guaranteed, and the programme has not yet reached clinical development or received regulatory approval.

Field

Content

Article Type

Deals

Acquirer

Eli Lilly

Target Company

Calytrix Bio

Deal Type

Definitive acquisition agreement

Announcement Date

16 November 2026

Transaction Status

Agreed

Maximum Potential Consideration

Up to $1.5 billion

Payment Currency

US dollars

Payment Form

Cash

Upfront Payment

Undisclosed

Contingent Consideration

Clinical and regulatory milestone payments

Guaranteed Upfront Value

Not disclosed

Lead Programme

Mutant calreticulin-targeting antibody

Lead Programme Development Stage

Preclinical

Drug Modality

Biparatopic antibody

Molecular Target

Mutant calreticulin

Target Abbreviation

Mutant CALR

Therapeutic Area

Haematology

Disease Focus One

Essential thrombocythaemia

Disease Focus Two

Myelofibrosis

Disease Category

Myeloproliferative neoplasms

Development Strategy

Precision targeting of disease-associated mutant calreticulin

Clinical-Stage Asset Included

Not according to supplied summary

Approved Medicine Included

No

What Happened

Eli Lilly agreed to acquire Calytrix Bio and its preclinical mutant calreticulin antibody programme.

Why It Matters

The acquisition strengthens Lilly's early-stage pipeline for rare blood disorders with significant unmet treatment needs.

Scientific Significance

The programme targets mutant calreticulin, a disease-associated molecular alteration in certain myeloproliferative neoplasms.

Strategic Significance

Expands Lilly's precision haematology research and development capabilities.

Financial Significance

Shareholders may receive up to $1.5 billion subject to milestone achievement.

Financial Clarification

The total potential value is not a disclosed upfront acquisition payment.

Development Clarification

The lead programme remains preclinical, and efficacy in patients has not been established.

Key Takeaway

Lilly plans to acquire Calytrix Bio for up to $1.5 billion to expand its mutant CALR-targeted haematology pipeline.

What to Watch

Acquisition completion, preclinical progress, first-in-human development plans and milestone achievements.

Primary Source

Calytrix Bio

Primary Source URL

https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html

Submitted Source

Reuters

Submitted Source URL

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-buy-calytrix-bio-up-15-billion-2026-11-16/

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page